Skip to main content

Diabetes

  • DRSI ReStore! Energy teams up with Charles Mattocks

    BOCA RATON, Fla. — Diabetica Research Solutions said its DRSI ReStore! Energy brand has teamed up with television personality and author Charles Mattocks.

    Mattocks, known to fans as "The Poor Chef," will make appearances with DRSI ReStore! Energy, including on such shows as "Dr. Oz," "Fox News" and "Oprah," as well as through his diabetes community website, newsletters and his blogs, while he continues testing recipes for diabetics using the supplement. Mattocks recently was diagnosed with Type 2 diabetes.

  • Lilly head continues call for medical innovation

    TOKYO — Eli Lilly leader John Lechleiter has become something of an evangelist for medical innovation lately.

    On Wednesday, the Lilly chairman, president and CEO spoke to the U.S./Japan Business Council in Tokyo to call for changes and policies in the biopharmaceutical industry that encourage innovation, or “reinventing invention,” as he called it.

  • DiabetesMine launches 2011 design challenge

    SAN FRANCISCO — An informational and community website for people with diabetes has kicked off its fourth annual design challenge, a Web-based competition that calls for fresh ideas for new devices, Web applications or other instruments designed to help people live better with the disease.

  • UltiMed introduces 50-count needles offering for diabetes patients

    ST. PAUL, Minn. — UltiMed is offering 50-count pen needles for patients with diabetes, the company announced.

    The company said the needles would give diabetes patients a high-quality and cost-effective option for their pen needle supplies. Before, pen needles were dispensed in quantities of 100.

    UltiMed said its needles, manufactured in its De Smet, S.D., factory, are the only ones assembled in the United States.

  • New diabetes drug accepted for review by FDA

    PRINCETON, N.J. — The Food and Drug Administration has accepted a regulatory approval application for a Type 2 diabetes drug from Bristol-Myers Squibb and AstraZeneca, the two drug makers said Tuesday.

    The FDA accepted the application for dapagliflozin, an investigational drug for adults with the disease. The Centers for Disease Control and Prevention estimated that 1-in-11 U.S. adults has diabetes, with 90% to 95% of them having Type 2 diabetes.

    The agency expects to take action on the application in late October.

  • Walgreens joins CCA

    WASHINGTON — Walgreens on Friday joined the Care Continuum Alliance, an alliance of more than 200 stakeholders providing services across the continuum of care — from wellness and prevention to chronic condition management and complex care management.

  • Good and bad news from CDC's U.S. diabetes stats

    Alarming statistics are as common in the healthcare world as healthcare workers themselves, but some of the latest numbers from the Centers for Disease Control and Prevention are particularly dramatic: Nearly 26 million Americans have diabetes, the agency said in late January, and an estimated 79 million U.S. adults — representing more than one-third of all adults in the country — have prediabetes.

  • Gene mutation, Type 2 diabetes linked in study

    CATANZARO, Italy — A new study revealed that a single gene mutation might be the cause of Type 2 diabetes.

X
This ad will auto-close in 10 seconds